Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients-Reference-Cited by-同舟云学术

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

Published:2013-05 Issue:8 Volume:49 Page:1825-1835
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Harbeck N.,Schmitt M.,Meisner C.,Friedel C.,Untch M.,Schmidt M.,Sweep C.G.J.,Lisboa B.W.,Lux M.P.,Beck T.,Hasmüller S.,Kiechle M.,Jänicke F.,Thomssen C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Peto;Lancet,2012

2. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011;Goldhirsch;Ann Oncol,2011

3. Characteristics of the Level-of-Evidence-1 disease forecast cancer biomarkers urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1;Mengele;Expert Rev Mol Diagn,2010

4. External quality assessment of trans-European multicenter antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts;Sweep;Br J Cancer,1998

5. Clinical utility of Level-of-Evidence-1 disease forecast cancer biomarkers urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1;Schmitt;Expert Rev Mol Diagn,2010

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel and Vinblastine Increase Plasminogen Activator Inhibitor-1 Production in Human Breast Cancer MCF-7 Cells but Not MDA-MB-231 Cells;Biological and Pharmaceutical Bulletin;2024-09-10

2. Haemostatic Proteins as Markers of Disease Progression and Prognosis in Breast Cancer;2024-07-12

3. Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells;2024-05-19

4. Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts;Cancers;2024-03-05

5. The prognostic and predictive value of Ki-67 proliferation index and uPA/PAI-1 complex in serum for patients with early invasive breast cancer;Sanamed;2024